http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2190094-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebb6a553affdc364c91cffe3baf12564 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 |
| filingDate | 1995-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9358b1261437c3b4cff92536d5200a94 |
| publicationDate | 1995-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2190094-A1 |
| titleOfInvention | Treating conditions with (+)-liarozole |
| abstract | Methods and compositions are disclosed utilizing optically pure (+)-liarozole for the treatment of conditions supported by estrogen or caused by elevated estrogen levels such as estrogen-dependent breast cancer, gynecomastia, systemic lupus erythematosus and premature labor while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of liarozole. Methods and compositions are also disclosed utilizing optically pure (+)-liarozole for the treatment of conditions supported by or caused by elevated testosterone levels, such as hormone dependent prostate cancer. Further disclosed are methods and compositions using pure (+)-liarozole in combination with retinoic acid for enhancing therapy with retinoic acid, such as in the treatment of neuroectodermal and neuroepithelial malignancies, including glioma, promyelocytic leukemia and hormone-independent prostate cancer. |
| priorityDate | 1994-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.